top of page

Harbinger Venture Capital

Venture Capital

聯訊創投

Search

BMS acquisition of Turning Point Therapeutics at US$4.1 B closed on 8/15/2022

website2646
Aug 17, 2022
1 min read

https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-and-Turning-Point-Therapeutics-Announce-Expiration-of-HSR-Act-Waiting-Period-and-Clearance-from-Federal-Cartel-Office-of-Germany-Related-to-Pending-Acquisition-of-Turning-Point-Therapeutics/default.aspx

Recent Posts

BlossomHill Therapeutics Doses Patients in the First Cohort of the Phase 1/2 SOLARA Clinical Trial of BH-30643 for EGFR- and HER2-Mutated Non-Small Cell Lung Cancer

https://www.businesswire.com/news/home/20250122706462/en/BlossomHill-Therapeutics-Doses-Patients-in-the-First-Cohort-of-the-Phase-12-SOLA...

xMEMS XMC-2400: The World’s First 1mm-Thin Active Micro Cooling Fan on a Chip

xMEMS Introduces 1mm-Thin Active Micro Cooling “Fan on a Chip”

Repligen Announces Agreement to Acquire Chromatography Innovator Tantti

Repligen Announces Agreement to Acquire Chromatography (globenewswire.com)

Comments

bottom of page